Mirtazapine Cuts Meth Use in Australian Phase 3 Tina Trial

An Australian clinical trial has demonstrated that mirtazapine, an inexpensive antidepressant used for decades to treat depression and insomnia, can help people reduce their methamphetamine use by an average of seven days per month—offering the first evidence-based pharmacological treatment for a condition that currently has no approved medications anywhere in the world.

The Tina Trial, published in JAMA Psychiatry, enrolled 339 adults with moderate to severe methamphetamine use disorder across six outpatient clinics in Australia. Participants who took 30 milligrams of mirtazapine daily for 12 weeks reduced their meth use by an average of seven days out of every 28, compared with 4.8 days for those receiving placebo—a statistically significant difference that researchers say represents an important breakthrough in addiction medicine.

A Global Treatment Gap

Methamphetamine dependence affects an estimated 7.4 million people worldwide, including a disproportionate share of Australia's population. The highly addictive stimulant—known variously as meth, crystal, or ice—carries severe health risks including paranoia, suicidal ideation, cardiovascular complications, stroke, and premature death.

Despite the scale of the crisis, no medication has ever been approved to treat methamphetamine use disorder. Current treatment options are limited to behavioral interventions: counseling, residential rehabilitation, and contingency management programs that provide rewards for meeting abstinence goals. While these approaches help some individuals, dropout rates are high and most people who complete residential treatment relapse.

The absence of pharmacological options stands in stark contrast to opioid use disorder, where medications like methadone, buprenorphine, and naltrexone have transformed treatment outcomes and become standard of care. For people struggling with stimulant addiction, the lack of medication-assisted treatment has left a significant gap in clinical options.

From Depression Treatment to Addiction Medicine

Mirtazapine has been prescribed since the 1990s as an antidepressant, working primarily through antagonism of serotonin and histamine receptors to improve mood and sleep. Its safety profile is well-established, side effects are generally mild—primarily drowsiness and weight gain—and generic versions are inexpensive and widely available.

The hypothesis that mirtazapine might help with methamphetamine use emerged from preclinical research suggesting the drug could modulate brain reward pathways disrupted by chronic stimulant use. Two smaller Phase 2 trials conducted at a research clinic in San Francisco had previously found mirtazapine reduced meth use among men and transgender women who have sex with men, but those studies excluded women and people with depression, limiting their generalizability.

The Tina Trial was designed to test whether mirtazapine would work in a broader, more diverse population receiving treatment in community settings rather than specialized research facilities.

The Study Design

Researchers recruited 339 participants from six outpatient clinics across Australia. At baseline, participants were using methamphetamine an average of 22 days out of the previous 28—indicating heavy, near-daily use. The sample was intentionally diverse, including men and women, people with and without co-occurring depression, and individuals from various socioeconomic backgrounds.

Participants were randomly assigned to receive either 30 milligrams of mirtazapine daily or an identical placebo for 12 weeks. The primary outcome measure was reduction in methamphetamine use days, assessed through a combination of self-report and biological verification.

The results showed that mirtazapine recipients reduced their meth use by an average of seven days per month compared with 4.8 days for placebo—a difference of 2.2 days. While modest in absolute terms, the effect was statistically significant and clinically meaningful given the complete absence of alternative medications.

Importantly, the benefit was observed regardless of whether participants had depression at study entry, suggesting mirtazapine's effect on methamphetamine use is independent of its antidepressant properties. This finding implies the medication is acting directly on neural pathways involved in drug reward and craving, potentially restoring function to systems disrupted by chronic methamphetamine use.

Safety and Practical Advantages

The trial found no unexpected safety issues with mirtazapine when used for methamphetamine use disorder. The most commonly reported side effects—sedation and weight gain—are well-known from the drug's use in depression and were generally tolerable.

From a practical standpoint, mirtazapine offers several advantages over investigational treatments that require specialized administration. It is taken orally once daily, typically at bedtime due to its sedating effects. Patients can take it home; there is no need for daily clinic visits, supervised dosing, or the complex regulatory requirements that surround methadone and buprenorphine for opioid use disorder.

Because mirtazapine has been off-patent for years, generic formulations are inexpensive and available at virtually any pharmacy. Physicians are familiar with its use, reducing barriers to prescribing for patients who might benefit.

Limitations and Context

The study's authors are careful not to overstate the findings. A reduction of 2.2 use days per month, while statistically significant, leaves participants still using methamphetamine frequently. Mirtazapine is not a cure for stimulant use disorder, nor does it produce the kind of dramatic effect that medications for opioid use disorder can achieve.

The mechanism by which mirtazapine reduces methamphetamine use remains incompletely understood. The drug's effects on serotonin, norepinephrine, and histamine receptors may modulate the reward and withdrawal symptoms that drive continued use, but the precise neurobiological pathways have not been fully elucidated.

Additionally, the 12-week trial duration, while standard for Phase 3 studies, provides limited information about long-term effectiveness. Whether benefits persist beyond three months, whether participants would continue taking the medication indefinitely, and whether there are diminishing returns over time are questions that will require longer follow-up studies.

Regulatory Pathway

For mirtazapine to become a standard treatment for methamphetamine use disorder, regulatory agencies such as the U.S. Food and Drug Administration and Australia's Therapeutic Goods Administration would need to approve it specifically for this indication. The Tina Trial provides the kind of rigorous, large-scale efficacy data that typically supports such applications.

In the interim, physicians in many jurisdictions can prescribe mirtazapine off-label for methamphetamine use disorder. Professional guidelines from organizations like the Royal Australian and New Zealand College of Psychiatrists provide frameworks for off-label prescribing when evidence supports benefit and risks are well-characterized.

Whether health systems and insurers will cover mirtazapine for stimulant use disorder before formal regulatory approval remains to be seen. The drug's low cost—often less than $10 per month for generic formulations—means many patients could potentially access it even without insurance coverage.

Implications for Treatment Systems

The Tina Trial's findings arrive at a moment of growing recognition that stimulant use disorders require expanded treatment options. Overdose deaths involving methamphetamine have risen sharply in the United States, Australia, and other regions, often in combination with fentanyl contamination that makes the drug supply unpredictably lethal.

While behavioral therapies remain foundational to stimulant use disorder treatment, the availability of a medication that can reduce use even modestly may improve engagement and retention in counseling, support harm reduction goals, and provide clinicians with an additional tool for patients who have not responded to psychosocial interventions alone.

The study also highlights the potential for repurposing existing medications to address addiction. Rather than developing new chemical entities—a process that takes years and costs billions—researchers are increasingly looking at drugs already approved for other conditions that might modulate the neurobiology of substance use disorders.

For the millions of people worldwide struggling with methamphetamine dependence, the Tina Trial represents incremental but genuine progress. After decades with no pharmacological options, mirtazapine offers a first step toward medication-assisted treatment for stimulant use disorder—a proof of concept that additional research may build upon to develop even more effective interventions.